[1] Huang D Q, Singal A G, Kono Y, et al. Changing global epidemiology of liver cancer from 2010 to 2019: NASH is the fastest growing cause of liver cancer [J]. Cell Metabolism, 2022, 34(7): 969-977.e2.
[2] Devarbhavi H, Asrani S K, Arab J P, et al. Global burden of liver disease: 2023 update [J]. Journal of Hepatology, 2023, 79(2): 516-537.
[3] Mcglynn K A, Petrick J L, El-Serag H B, et al. Epidemiology of hepatocellular carcinoma [J]. Hepatology, 2020, 73(S1): 4-13.
[4] Zhang C H, Cheng Y, Zhang S, et al. Changing epidemiology of hepatocellular carcinoma in Asia [J]. Liver International, 2022, 42(9): 2029-2041.
[5] Bucci L, Garuti F, Camelli V, et al. Comparison between alcohol- and hepatitis C virus-related hepatocellular carcinoma: clinical presentation, treatment and outcome [J]. Aliment Pharmacol Ther, 2016, 43(3): 385-399.
[6] Huang D Q, Mathurin P, Cortez-pinto H, et al. Global epidemiology of alcohol-associated cirrhosis and HCC: trends, projections and risk factors [J]. Nat Rev Gastroenterol Hepatol, 2023, 20(1): 37-49.
[7] Batt N M, Rodrigues B, Bloom S, et al. Metabolic-associated fatty liver disease and hepatocellular carcinoma: a prospective study of characteristics and response to therapy [J]. J Gastroenterol Hepatol, 2024, 39(6): 1048-1056.
[8] Yue T, Xu M, Cai T, et al. Gender disparity and temporal trend of liver cancer in China from 1990 to 2019 and predictions in a 25-year period [J]. Front Public Health, 2022, 10: 956712.
[9] Costentin C E, Sogni P, Falissard B, et al. Geographical disparities of outcomes of hepatocellular carcinoma in France: the heavier burden of alcohol compared to hepatitis C [J]. Dig Dis Sci, 2020, 65(1): 301-311.
[10] Ganne-Carrié N, Nahon P. Hepatocellular carcinoma in the setting of alcohol-related liver disease [J]. J Hepatol, 2019, 70(2): 284-293.
[11] Gratacós-ginès J, Ariño S, Sancho-bru P, et al. MetALD: clinical aspects, pathophysiology and treatment [J]. JHEP Rep, 2025, 7(2): 101250.
[12] Yun B, Park H, Ahn S H, et al. Liver cancer risk across metabolic dysfunction-associated steatotic liver disease and/or alcohol: a nationwide study [J]. Am J Gastroenterol, 2025, 120(2): 410-419.
[13] Zeng R W, Ong C E Y, Ong E Y H, et al. Global prevalence, clinical characteristics, surveillance, treatment allocation, and outcomes of alcohol-associated hepatocellular carcinoma [J]. Clin Gastroenterol Hepatol, 2024, 22(12): 2394-2402.e15.
[14] Jacob R, Prince D S, Kench C, et al. Alcohol and its associated liver carcinogenesis [J]. J Gastroenterol Hepatol, 2023, 38(8): 1211-1217.
[15] Seo W, Gao Y, He Y, et al. ALDH2 deficiency promotes alcohol-associated liver cancer by activating oncogenic pathways via oxidized DNA-enriched extracellular vesicles [J]. J Hepatol, 2019, 71(5): 1000-1011.
[16] Buch S, Stickel F, Trépo E, et al. A genome-wide association study confirms PNPLA3 and identifies TM6SF2 and MBOAT7 as risk loci for alcohol-related cirrhosis [J]. Nat Genet, 2015, 47(12): 1443-1448.
[17] Jiang Y, Han Q, Zhao H, et al. The mechanisms of HBV-induced hepatocellular carcinoma [J]. J Hepatocell Carcinoma, 2021, 8: 435-450.
[18] Vescovo T, Refolo G, Vitagliano G, et al. Molecular mechanisms of hepatitis C virus-induced hepatocellular carcinoma [J]. Clin Microbiol Infect, 2016, 22(10): 853-861.
[19] Singal A G, Yopp A C, Gupta S, et al. Failure rates in the hepatocellular carcinoma surveillance process [J]. Cancer Prev Res (Phila), 2012, 5(9): 1124-1130.
[20] Beale G, Chattopadhyay D, Gray J, et al. AFP, PIVKAII, GP3, SCCA-1 and follisatin as surveillance biomarkers for hepatocellular cancer in non-alcoholic and alcoholic fatty liver disease [J]. BMC Cancer, 2008, 8: 200.
[21] Saito M, Yano Y, Hirano H, et al. The serum level of NX-DCP-R, but not DCP, is not increased in alcoholic liver disease without hepatocellular carcinoma [J]. Cancer Biomark, 2016, 16(1): 171-180.
[22] Lehrich B M, Zhang J, Monga S P, et al. Battle of the biopsies: role of tissue and liquid biopsy in hepatocellular carcinoma [J]. J Hepatol, 2024, 80(3): 515-530.
[23] Simmons O, Fetzer D T, Yokoo T, et al. Predictors of adequate ultrasound quality for hepatocellular carcinoma surveillance in patients with cirrhosis [J]. Aliment Pharmacol Ther, 2017, 45(1): 169-177.
[24] Mokrane F Z, Lu L, Vavasseur A, et al. Radiomics machine-learning signature for diagnosis of hepatocellular carcinoma in cirrhotic patients with indeterminate liver nodules [J]. Eur Radiol, 2020, 30(1): 558-570.
[25] Yang X, Yang C, Zhang S, et al. Precision treatment in advanced hepatocellular carcinoma [J]. Cancer Cell, 2024, 42(2): 180-197.
[26] Pfister D, Núñez N G, Pinyol R, et al. NASH limits anti-tumour surveillance in immunotherapy-treated HCC [J]. Nature, 2021, 592(7854): 450-456.
[27] Bruix J, Raoul J L, Sherman M, et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial [J]. J Hepatol, 2012, 57(4): 821-829.
[28] Lo C M, Ngan H, Tso W K, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma [J]. Hepatology, 2002, 35(5): 1164-1171.
[29] Ganne-Carrié N, Nahon P, Chaffaut C, et al. Impact of cirrhosis aetiology on incidence and prognosis of hepatocellular carcinoma diagnosed during surveillance [J]. JHEP Rep, 2021, 3(3): 100285.
[30] Costentin C E, Mourad A, Lahmek P, et al. Hepatocellular carcinoma is diagnosed at a later stage in alcoholic patients: results of a prospective, nationwide study [J]. Cancer, 2018, 124(9): 1964-1972. |
